Over the last decade, preclinical studies and clinical trials have demonstrated that compared to other breast cancer subtypes, TNBC has higher immunogenicity, higher enrichment of tumor-infiltrating lymphocytes, and higher levels of programmed cell death ligand 1 (PD-L1) [5]. This evidence concerns the gene CD274 and breast carcinoma.